Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development Aprea AB CanBas Co Ltd Cotinga Pharmaceuticals Inc Innovation Pharmaceuticals Inc ORCA Therapeutics BV OSE Immunotherapeutics Quark Pharmaceuticals Inc Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles APR-246 - Drug Profile Product Description Mechanism Of Action R&D Progress AU-14022 - Drug Profile Product Description Mechanism Of Action R&D Progress CBS-9106 - Drug Profile Product Description Mechanism Of Action R&D Progress contusugene ladenovec - Drug Profile Product Description Mechanism Of Action R&D Progress COTI-2 - Drug Profile Product Description Mechanism Of Action R&D Progress D-12PGJ3 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate p53 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Kevetrin - Drug Profile Product Description Mechanism Of Action R&D Progress MHY-449 - Drug Profile Product Description Mechanism Of Action R&D Progress MJ-05 - Drug Profile Product Description Mechanism Of Action R&D Progress Oncolytic Viruses to Activate p53 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress OSE-2101 - Drug Profile Product Description Mechanism Of Action R&D Progress p28 - Drug Profile Product Description Mechanism Of Action R&D Progress QPAL-1 - Drug Profile Product Description Mechanism Of Action R&D Progress QPI-1002 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Activate p53 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress SGT-53 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate p53 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate p53 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress ZMC-1 - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones Featured News & Press Releases Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment Feb 08, 2018: Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed Jan 25, 2018: Cotinga Pharmaceuticals Announces Publication of Positive Data from Preclinical Study of COTI-2 in PLOS One Jan 25, 2018: OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications Dec 27, 2017: Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial Dec 19, 2017: Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies Dec 07, 2017: OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment Nov 15, 2017: Critical Outcome Technologies Announces Pharmacokinetic Data From Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies Nov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference Nov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting Nov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting Oct 16, 2017: Karolinska Developments portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer Oct 11, 2017: Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma Sep 14, 2017: Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Products under Development by Companies, H1 2018 (Contd..3), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Aprea AB, H1 2018 Pipeline by CanBas Co Ltd, H1 2018 Pipeline by Cotinga Pharmaceuticals Inc, H1 2018 Pipeline by Innovation Pharmaceuticals Inc, H1 2018 Pipeline by ORCA Therapeutics BV, H1 2018 Pipeline by OSE Immunotherapeutics, H1 2018 Pipeline by Quark Pharmaceuticals Inc, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Dormant Products, H1 2018 (Contd..2), H1 2018 Dormant Products, H1 2018 (Contd..3), H1 2018 Dormant Products, H1 2018 (Contd..4), H1 2018 Dormant Products, H1 2018 (Contd..5), H1 2018 Discontinued Products, H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018